The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
<p>The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.</p>
Gorde:
| Egile nagusia: | Seyed Reza Mousavi (13223324) (author) |
|---|---|
| Beste egile batzuk: | Alihasan Rahmani (22676321) (author), Maryam Amini Pouya (22676324) (author), Elnaz Zabihi Eidgahi (22676327) (author), Mohamad Delirrad (22676330) (author), Hamed Hosseini (3480455) (author), Alireza Ghassemi Toussi (22676333) (author), Behnaz Hedayatjoo (22676336) (author), Seyyedeh Maryam Afshani (22676339) (author), Mohammad Amin Ghobadi (22676342) (author), Mohammad Reza Shahidi (22676345) (author), Seyed Amirhossein Mousavi (22676348) (author), Maryam Barghbani (22676351) (author), Mahdi Jannati Yazdan Abad (22676354) (author) |
| Argitaratua: |
2025
|
| Gaiak: | |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Antzeko izenburuak
-
Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
nork: Seyed Reza Mousavi (13223324)
Argitaratua: (2025) -
Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
nork: Seyed Reza Mousavi (13223324)
Argitaratua: (2025) -
Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
nork: Seyed Reza Mousavi (13223324)
Argitaratua: (2025) -
Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
nork: Seyed Reza Mousavi (13223324)
Argitaratua: (2025) -
Table 1_Immune responses in pulmonary sarcoidosis following COVID-19.docx
nork: Anna Starshinova (22571846)
Argitaratua: (2025)